COMP <GO>
CDRE vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Cadre Holdings Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CDRE 6
— ABBV 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $31.10 (+3.81%) • MKT CAP: $1.33B
roic
11.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CDRE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CDRE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 42.50% | 70.20% | -27.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 11.00% | 29.00% | -18.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.5x | 33.3x | -12.80 | CDRE | /valuation <GO> |
| Free Cash Flow Yield | 4.27% | 3.47% | +0.80 | CDRE | /fcf-yield <GO> |
| Operating Margin | 11.00% | 24.60% | -13.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 7.20% | 6.90% | +0.30 | CDRE | /net-margins <GO> |
| Revenue Growth (YoY) | 7.50% | 8.60% | -1.10 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.16% | 2.27% | -1.11 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.32 | 5.33 | -2.01 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | CDRE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.2 | 65.1 | +3.10 | CDRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.1x | 113.1x | -85.00 | CDRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.33B | $513.86B | -$512.53B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CDRE REV | ABBV REV | CDRE GROSS % | ABBV GROSS % | CDRE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $610.3M | $61.16B | 42.5% | 70.2% | $56.8M | $17.82B |
| FY 2024 | $567.6M | $56.33B | 41.1% | 70.0% | $26.1M | $17.83B |
| FY 2023 | $482.5M | $54.32B | — | — | $73.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CDRE // BETA —
ABBV // BETA 1.15